Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by STEPHEN GOTTSCHALK and CLIONA ROONEY.
STEPHEN GOTTSCHALK
Connection Strength
4.985
CLIONA ROONEY
  1. Adoptive T-Cell Immunotherapy. Curr Top Microbiol Immunol. 2015; 391:427-54.
    View in: PubMed
    Score: 0.525
  2. Harnessing the immune system to potentiate oncolytics. Mol Ther. 2014 Feb; 22(2):239-240.
    View in: PubMed
    Score: 0.493
  3. T cell therapies. Ernst Schering Found Symp Proc. 2006; (4):69-82.
    View in: PubMed
    Score: 0.281
  4. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma. 2005 Jan; 46(1):1-10.
    View in: PubMed
    Score: 0.262
  5. A Costimulatory CAR Improves TCR-based Cancer Immunotherapy. Cancer Immunol Res. 2022 04 01; 10(4):512-524.
    View in: PubMed
    Score: 0.217
  6. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunol Res. 2019 03; 7(3):363-375.
    View in: PubMed
    Score: 0.174
  7. Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells. Front Med (Lausanne). 2018; 5:343.
    View in: PubMed
    Score: 0.172
  8. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy. 2019 02; 21(2):212-223.
    View in: PubMed
    Score: 0.171
  9. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139.
    View in: PubMed
    Score: 0.162
  10. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017 11; 7(11):1238-1247.
    View in: PubMed
    Score: 0.158
  11. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
    View in: PubMed
    Score: 0.157
  12. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
    View in: PubMed
    Score: 0.133
  13. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
    View in: PubMed
    Score: 0.122
  14. Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer. 2012 Oct; 59(4):758-61.
    View in: PubMed
    Score: 0.105
  15. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther. 2011 Dec; 19(12):2133-43.
    View in: PubMed
    Score: 0.103
  16. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy. 2011 May; 13(5):518-22.
    View in: PubMed
    Score: 0.101
  17. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010 Nov-Dec; 33(9):983-90.
    View in: PubMed
    Score: 0.098
  18. A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther. 2011 Jan; 19(1):211-7.
    View in: PubMed
    Score: 0.098
  19. IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol. 2010 Oct 01; 185(7):4223-32.
    View in: PubMed
    Score: 0.097
  20. Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation. Immunotherapy. 2010 Sep; 2(5):663-71.
    View in: PubMed
    Score: 0.097
  21. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009 Oct; 17(10):1779-87.
    View in: PubMed
    Score: 0.089
  22. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12; 113(11):2442-50.
    View in: PubMed
    Score: 0.086
  23. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007 Jun 15; 67(12):5957-64.
    View in: PubMed
    Score: 0.078
  24. Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J Immunother. 2007 Jan; 30(1):96-107.
    View in: PubMed
    Score: 0.075
  25. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005; 56:29-44.
    View in: PubMed
    Score: 0.066
  26. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug; 27(4):317-27.
    View in: PubMed
    Score: 0.063
  27. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003 May-Jun; 26(3):241-56.
    View in: PubMed
    Score: 0.058
  28. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
    View in: PubMed
    Score: 0.055
  29. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711.
    View in: PubMed
    Score: 0.054
  30. Immunotherapy for Hodgkin's disease. Ann Hematol. 2002; 81 Suppl 2:S39-42.
    View in: PubMed
    Score: 0.053
  31. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021 07 29; 138(4):318-330.
    View in: PubMed
    Score: 0.052
  32. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
    View in: PubMed
    Score: 0.043
  33. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
    View in: PubMed
    Score: 0.039
  34. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
    View in: PubMed
    Score: 0.039
  35. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas. Methods Mol Biol. 2017; 1532:255-265.
    View in: PubMed
    Score: 0.038
  36. Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells. J Immunother. 2014 Oct; 37(8):407-15.
    View in: PubMed
    Score: 0.032
  37. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother. 2014 May; 37(4):193-203.
    View in: PubMed
    Score: 0.031
  38. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
    View in: PubMed
    Score: 0.030
  39. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood. 2013 Jan 03; 121(1):207-18.
    View in: PubMed
    Score: 0.028
  40. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012 Aug; 20(8):1622-32.
    View in: PubMed
    Score: 0.028
  41. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68.
    View in: PubMed
    Score: 0.027
  42. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011 Dec; 19(12):2258-68.
    View in: PubMed
    Score: 0.026
  43. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011 Sep; 13(8):976-86.
    View in: PubMed
    Score: 0.025
  44. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 02; 117(22):5835-49.
    View in: PubMed
    Score: 0.025
  45. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010 Oct; 12(6):743-9.
    View in: PubMed
    Score: 0.024
  46. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45.
    View in: PubMed
    Score: 0.020
  47. Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates. Mol Ther. 2007 Feb; 15(2):386-92.
    View in: PubMed
    Score: 0.019
  48. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006 Nov 01; 108(9):2942-9.
    View in: PubMed
    Score: 0.018
  49. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May; 47(5):837-42.
    View in: PubMed
    Score: 0.018
  50. Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma. 2006 Jan; 6(4):342-7.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.